PTPRD inhibitors and uses thereof
AssigneesArizona Board of Regents on Behalf of the University of Arizona, The United States Government as respresented by the Department of Veterans Affairs, University of Kentucky Research Foundation
InventorsGeorge Richard Uhl, Ian M. Henderson, Wei Wang, Thomas Prisinzano
Life of this patent
Estimating the term…
Abstract
Disclosed are small molecule PTPRD inhibitors and uses thereof. Methods of using the PTPRD inhibitors include methods of treating, preventing, or delaying the progression of a disorder responsive to PTPRD inhibition, including for example nicotine dependence, addiction, obesity, metabolic syndrome, and substance-use disorders such as stimulant-use disorders and opioid-use disorders.
Claims16
A compound having a structure represented by Formula (I):
- wherein R1 is hydrogen, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C2-C4 alkoxy, C2-C4 haloalkoxy, C1-C4 alkylamino, C1-C4 acetyl, or (C1-C4)(C1-C4) dialkylamino;
- R2 is C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C2-C4 alkoxy, C2-C4 haloalkoxy, C1-C4 alkylamino, or (C1-C4)(C1-C4) dialkylamino;
- R3 is hydrogen or has a structure represented by the formula:
- wherein R9-R13, when present, are independently hydrogen, methyl, —OCH3, —CN, —CF3, —OCF3, or halide;
- R14, when present, is hydrogen or halide;
- R15, when present, is methyl or halide;
- Y, when present, is CH or N;
- and
- R16-18, when present, are independently hydrogen, hydroxyl, or halide;
- or a pharmaceutically acceptable salt thereof,
- provided that when R1 is hydrogen and R2 is methyl, then R3 is not
Dependencies are inferred from the claim text.